PRAX
What one share of Praxis Precision Medicines holds
Pharmaceutical Preparations
We are a fully integrated, leading central nervous system, or CNS, precision neuroscience biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance.
Praxis Precision Medicines’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$12.86 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$11.58 |
| Cash and investments | $49.21 |
| Book value | $48.04 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$398.94 | $1.01 | −$328.74 | — | −$749.20 |
| 2020 | — | −$117.86 | $0.00 | −$88.19 | — | — |
| 2021 | — | −$59.03 | $0.37 | −$44.38 | — | $83.05 |
| 2022 | $0.00 | −$69.65 | $0.14 | −$60.36 | — | $23.12 |
| 2023 | $0.37 | −$18.69 | $0.01 | −$16.86 | — | $7.92 |
| 2024 | $0.48 | −$10.21 | $0.00 | −$7.36 | — | $22.93 |
| 2025 | $0.00 | −$13.48 | $0.00 | −$11.07 | — | $34.85 |